

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1-22. (Canceled)

<sup>1</sup>/~~23~~ (Currently amended). An isolated antibody or antigen binding fragment thereof which:

(a) specifically binds a factor IX/IXa Gla domain; and

(b) comprises a heavy chain and a light chain variable region further wherein:

(i) the heavy chain variable region comprises a CDR1 which is SEQ ID NO:10, a CDR2 which is SEQ ID NO:11 and a CDR3 which is SEQ ID NO:12; and

(ii) the light chain variable region comprises ~~an~~ a CDR1 which is SEQ ID NO:13, ~~and~~ le a CDR2 which is SEQ ID NO:14, and ~~an~~ a CDR3 which is SEQ ID NO:15.

<sup>2</sup>/~~24~~ (Previously presented). A composition comprising the antibody or antigen binding fragment of Claim <sup>1</sup>/~~23~~ and a carrier, excipient or stabilizer.

<sup>3</sup>/~~25~~ (Previously presented). The composition of Claim <sup>2</sup>/~~24~~, wherein the carrier, excipient or stabilizer is pharmaceutically-acceptable.

<sup>4</sup>/~~26~~ (Previously presented). The composition of Claim <sup>3</sup>/~~25~~, which is sterile.

<sup>5</sup>/~~27~~ (Previously presented). The composition of Claim <sup>4</sup>/~~26~~ further comprising a thrombolytic agent.

<sup>6</sup>/~~28~~ (Previously presented). The composition of Claim <sup>5</sup>/~~27~~ wherein the thrombolytic agent is tissue plasminogen activator.

<sup>7</sup>/~~29~~ (Previously presented). The composition of Claim <sup>5</sup>/~~27~~ wherein the thrombolytic agent is streptokinase.

<sup>8</sup>/~~30~~ (Previously presented). The composition of Claim <sup>5</sup>/~~27~~ wherein the thrombolytic agent is urokinase.

<sup>9</sup>  
~~31~~ (Previously presented). The composition of Claim <sup>5</sup>~~27~~ wherein the thrombolytic agent is an isolated streptokinase plasminogen.

<sup>10</sup>  
~~32~~ (Previously presented). The composition of Claim <sup>4</sup>~~26~~ which is lyophilized.

<sup>11</sup>  
~~33~~ (Previously presented). The composition of Claim <sup>4</sup>~~26~~ which is liquid.

<sup>12</sup>  
~~34~~ (Previously presented). The composition of Claim <sup>5</sup>~~27~~ which is lyophilized.

<sup>13</sup>  
~~35~~ (Previously presented). The composition of Claim <sup>5</sup>~~27~~ which is liquid.

<sup>14</sup>  
~~36~~ (Previously presented). An article of manufacture comprising;

(a) a container;

(b) a label on said container; and

(c) a composition comprising an antibody or antibody fragment of Claim <sup>1</sup>~~23~~ within said container;

wherein the composition is effective for treating a coagulation disorder, and optionally a label on said container indicating that the composition can be used for treating a coagulopathic disorder.

<sup>15</sup>  
~~37~~ (Previously presented). An article of manufacture comprising:

(a) a container;

(b) a label on said container; and

(c) the composition of Claim <sup>4</sup>~~26~~ within said container;

wherein the composition is effective for treating a coagulation disorder, and optionally a label on said container indicating that the composition can be used for treating a coagulopathic disorder.

<sup>16</sup>  
~~38~~ (Previously presented). An article of manufacture comprising:

- (a) a container;
- (b) a label on said container; and
- (c) the composition of Claim ~~27~~<sup>5</sup> within said container;

wherein the composition is effective for treating a coagulation disorder, and optionally a label on said container indicating that the composition can be used for treating a coagulopathic disorder.

~~17~~<sup>17</sup> (Previously presented). An article of manufacture comprising:

- (a) a container;
- (b) a label on said container; and
- (c) the composition of Claim ~~28~~<sup>6</sup> within said container; wherein the composition is effective for treating a coagulation disorder, and optionally a label on said container indicating that the composition can be used for treating a coagulopathic disorder.

~~18~~<sup>18</sup> (Previously presented). An article of manufacture comprising:

- (a) a container;
- (b) a label on said container; and
- (c) the composition of Claim ~~29~~<sup>7</sup> within said container;

wherein the composition is effective for treating a coagulation disorder, and optionally a label on said container indicating that the composition can be used for treating a coagulopathic disorder.

~~19~~<sup>19</sup> (Previously presented). An article of manufacture comprising:

- (a) a container;
- (b) a label on said container; and
- (c) the composition of Claim ~~30~~<sup>8</sup> within said container;

wherein the composition is effective for treating a coagulation disorder, and optionally a label on said container indicating that the composition can be used for treating a coagulopathic disorder.

<sup>20</sup>/<sub>42</sub> (Previously presented). An article of manufacture comprising:

- (a) a container;
- (b) a label on said container; and
- (c) the composition of Claim <sup>9</sup>/<sub>31</sub> within said container;

wherein the composition is effective for treating a coagulation disorder, and optionally a label on said container indicating that the composition can be used for treating a coagulopathic disorder.